Cargando…

Considerations for vaccinating children against COVID-19

COVID-19 vaccines have been introduced in children and adolescents in many countries. However, high levels of community transmission and infection-derived immunity make the decision to introduce COVID-19 vaccination of children in countries yet to do so particularly challenging. For example, other v...

Descripción completa

Detalles Bibliográficos
Autores principales: Hart, John D, Ong, Darren Suryawijaya, Chokephaibulkit, Kulkanya, Ong-Lim, Anna T, Vereti, Ilisapeci, Crawford, Nigel W, Russell, Fiona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373744/
https://www.ncbi.nlm.nih.gov/pubmed/37487674
http://dx.doi.org/10.1136/bmjpo-2023-001964
_version_ 1785078625514553344
author Hart, John D
Ong, Darren Suryawijaya
Chokephaibulkit, Kulkanya
Ong-Lim, Anna T
Vereti, Ilisapeci
Crawford, Nigel W
Russell, Fiona
author_facet Hart, John D
Ong, Darren Suryawijaya
Chokephaibulkit, Kulkanya
Ong-Lim, Anna T
Vereti, Ilisapeci
Crawford, Nigel W
Russell, Fiona
author_sort Hart, John D
collection PubMed
description COVID-19 vaccines have been introduced in children and adolescents in many countries. However, high levels of community transmission and infection-derived immunity make the decision to introduce COVID-19 vaccination of children in countries yet to do so particularly challenging. For example, other vaccine preventable diseases, including measles and polio, generally have far higher childhood morbidity and mortality in low-income and middle-income countries (LMICs) than COVID-19, and coverage with these vaccines has declined during the pandemic. Many countries are yet to introduce pneumococcal conjugate and rotavirus vaccines for children, which prevent common causes of childhood death, or human papillomavirus vaccine for adolescents. The Pfizer and Moderna COVID-19 vaccines that have been widely tested in children and adolescents had a positive risk-benefit profile at the time they were tested. However, the benefit is less compared with other life-saving vaccines in this age group, particularly in LMICs and settings with widespread infection-derived immunity. The resources required for rollout may also pose a considerable challenge in LMICs. In this paper, we describe COVID-19 in children, with a focus on LMICs, and summarise the published literature on safety, efficacy and effectiveness of COVID-19 vaccination in children and adolescents. We highlight the complexity of decision-making regarding COVID-19 vaccination of children now that most of this low-risk population benefit from infection-derived immunity. We emphasise that at-risk groups should be prioritised for COVID-19 vaccination; and that if COVID-19 vaccines are introduced for children, the opportunity should be taken to improve coverage of routine childhood vaccines and preventative healthcare. Additionally, we highlight the paucity of epidemiological data in LMICs, and that for future epidemics, measures need to be taken to ensure equitable access to safe and efficacious vaccines before exposure to infection.
format Online
Article
Text
id pubmed-10373744
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-103737442023-07-28 Considerations for vaccinating children against COVID-19 Hart, John D Ong, Darren Suryawijaya Chokephaibulkit, Kulkanya Ong-Lim, Anna T Vereti, Ilisapeci Crawford, Nigel W Russell, Fiona BMJ Paediatr Open Review COVID-19 vaccines have been introduced in children and adolescents in many countries. However, high levels of community transmission and infection-derived immunity make the decision to introduce COVID-19 vaccination of children in countries yet to do so particularly challenging. For example, other vaccine preventable diseases, including measles and polio, generally have far higher childhood morbidity and mortality in low-income and middle-income countries (LMICs) than COVID-19, and coverage with these vaccines has declined during the pandemic. Many countries are yet to introduce pneumococcal conjugate and rotavirus vaccines for children, which prevent common causes of childhood death, or human papillomavirus vaccine for adolescents. The Pfizer and Moderna COVID-19 vaccines that have been widely tested in children and adolescents had a positive risk-benefit profile at the time they were tested. However, the benefit is less compared with other life-saving vaccines in this age group, particularly in LMICs and settings with widespread infection-derived immunity. The resources required for rollout may also pose a considerable challenge in LMICs. In this paper, we describe COVID-19 in children, with a focus on LMICs, and summarise the published literature on safety, efficacy and effectiveness of COVID-19 vaccination in children and adolescents. We highlight the complexity of decision-making regarding COVID-19 vaccination of children now that most of this low-risk population benefit from infection-derived immunity. We emphasise that at-risk groups should be prioritised for COVID-19 vaccination; and that if COVID-19 vaccines are introduced for children, the opportunity should be taken to improve coverage of routine childhood vaccines and preventative healthcare. Additionally, we highlight the paucity of epidemiological data in LMICs, and that for future epidemics, measures need to be taken to ensure equitable access to safe and efficacious vaccines before exposure to infection. BMJ Publishing Group 2023-07-24 /pmc/articles/PMC10373744/ /pubmed/37487674 http://dx.doi.org/10.1136/bmjpo-2023-001964 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Hart, John D
Ong, Darren Suryawijaya
Chokephaibulkit, Kulkanya
Ong-Lim, Anna T
Vereti, Ilisapeci
Crawford, Nigel W
Russell, Fiona
Considerations for vaccinating children against COVID-19
title Considerations for vaccinating children against COVID-19
title_full Considerations for vaccinating children against COVID-19
title_fullStr Considerations for vaccinating children against COVID-19
title_full_unstemmed Considerations for vaccinating children against COVID-19
title_short Considerations for vaccinating children against COVID-19
title_sort considerations for vaccinating children against covid-19
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373744/
https://www.ncbi.nlm.nih.gov/pubmed/37487674
http://dx.doi.org/10.1136/bmjpo-2023-001964
work_keys_str_mv AT hartjohnd considerationsforvaccinatingchildrenagainstcovid19
AT ongdarrensuryawijaya considerationsforvaccinatingchildrenagainstcovid19
AT chokephaibulkitkulkanya considerationsforvaccinatingchildrenagainstcovid19
AT onglimannat considerationsforvaccinatingchildrenagainstcovid19
AT veretiilisapeci considerationsforvaccinatingchildrenagainstcovid19
AT crawfordnigelw considerationsforvaccinatingchildrenagainstcovid19
AT russellfiona considerationsforvaccinatingchildrenagainstcovid19